Home TRIMTECH Therapeutics

TRIMTECH Therapeutics

In operation
Seed Round Financing
Developer of Small Molecule Degraders for Protein Aggregates

Basic Information

TRIMTECH Therapeutics' mission is to create novel, highly differentiated, orally active small-molecule degraders of protein aggregates to combat major neurodegenerative and inflammatory diseases with significant medical needs. The company's platform offers oral therapeutic drugs with specificity for aggregated proteins, ensuring safety and the potential for personalized treatment approaches targeting neurological, inflammatory, and oncological diseases, enabling patients to access effective and safe treatment options.
TRIMTECH Therapeutics
Cambridge,England,United Kingdom
15~50 people
January 01, 2023
--